Seikagaku Benefits from Market Rebound in Japan and Abroad

Seikagaku reported FY 2Q21 orthopedic sales of $42.3 million (¥4,402), +35.9% vs. FY 2Q20. Compared to the same period in 2019, the company grew +2.5%. For the full fiscal year ending March 31, 2022, Seikagaku expects growth of +16% vs. 2020.

The company is rounding the corner on offsetting drug price reductions in Japan via market share...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us